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Abstract
Background: Congenital diaphragmatic hernia (CDH) is a congenital anomaly with high mortality and morbidity
mainly due to pulmonary hypoplasia and hypertension. Temporary fetal tracheal occlusion to promote prenatal
lung growth may improve survival. Entrapment of lung fluid stretches the airways, leading to lung growth.
Methods: Fetal endoluminal tracheal occlusion (FETO) is performed by percutaneous sono-endoscopic insertion of
a balloon developed for interventional radiology. Reversal of the occlusion to induce lung maturation can be
performed by fetoscopy, transabdominal puncture, tracheoscopy, or by postnatal removal if all else fails.
Results: FETO and balloon removal have been shown safe in experienced hands. This paper deals with the
technical aspects of balloon insertion and removal. While FETO is invasive, it has minimal maternal risks yet can
cause preterm birth potentially offsetting its beneficial effects.
Conclusion: For left-sided severe and moderate CDH, the procedure is considered investigational and is currently
being evaluated in a global randomized clinical trial (https://www.totaltrial.eu/). The procedure can be clinically
offered to fetuses with severe right-sided CDH.
Keywords: FETO, Fetal endoluminal tracheal occlusion, CDH, Congenital diaphragmatic hernia, Fetal surgery,
Fetoscopy
Background
Congenital diaphragmatic hernia (CDH) is a life-
threatening condition affecting up to 3 in 10,000 live
born babies [1]. The diaphragmatic defect allows abdom-
inal organs to herniate into the thorax which prevents
normal lung development. Depending on the side and
size of the defect, this may be the liver, bowel, spleen,
and/or stomach. The majority of defects are left sided
(LCDH 85%). Thirteen percent are right sided (RCDH),
and bilateral defects or other forms occur very rarely.
Associated anomalies are frequent and should be ruled
out by imaging and genetic testing as they independently
influence survival and morbidity. In most registries cur-
rently, survival is approximately 70% depending on the
case mix and location of treatment [2]. Surviving pa-
tients may suffer from not only medium and long-term
morbidity predominantly respiratory in nature, but also
gastro-esophageal reflux, failure to thrive, and less com-
mon orthopedic or other problems.
Individualized prognosis of isolated CDH can be
made prenatally by using the lung size, the presence of
the liver in the thorax, and the side of the defect [3]. Pa-
tients with predicted poor prognosis can be offered ex-
perimental fetal therapy. To improve survival, the
intervention should reverse pulmonary hypoplasia (i.e.,
stimulate lung growth) before birth. Historically, this
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was attempted by anatomical repair of the defect in
utero. The results of this approach were suboptimal [4].
Also, the anatomic defect itself can be relatively easily
managed after birth hence it is not the problem. An al-
ternative strategy, based on the clinical observation that
fetuses with laryngeal atresia have larger lungs, led to
animal experiments that demonstrated that fetal tracheal
occlusion reverses experimental pulmonary hypoplasia
[5]. Tracheal occlusion leads to accumulation of lung
fluid which in turn causes lung stretch. This activates a
pathway that leads to proliferation and increased growth
of the airways and pulmonary vessels, nicely summa-
rized in the acronym PLUG: “Plug the Lung Until it
Grows” (PLUG) [6]. However, when the occlusion is
maintained until birth, the number of type II pneumo-
cytes is abnormally low, leading to a relative surfactant
deficiency [7]. By reversing the tracheal occlusion before
birth, the balance between type I and type II pneumo-
cytes at birth is more optimal. This is captured in the
concept “plug-unplug sequence,” and reversal of occlu-
sion is an important component in the fetal treatment
strategy [7]. Nowadays, tracheal occlusion is uniquely
performed by minimally invasive fetal endoluminal tra-
cheal occlusion (FETO) and performed under sono-
endoscopic guidance. This is a percutaneous procedure
in which a latex balloon is endoscopically positioned
above the carina and inflated to occlude the trachea [8]
(Fig. 1). The present paper describes the instrumenta-
tion and the technical aspects of the FETO procedure as
currently performed by the above clinical research con-
sortium within their clinical trial.
Methods
Selection of fetuses
CDH is typically diagnosed during mid-gestation on
screening ultrasound. Following the diagnosis (or suspi-
cion thereof ), patients are best referred to a tertiary cen-
ter where this condition is routinely managed after birth.
Patients will be reassessed with targeted ultrasound and
magnetic resonance imaging (MRI) and will be offered
genetic testing (today this is by micro-array analysis) [9].
This has two purposes, (1) to rule out associated struc-
tural or genetic anomalies, which themselves may
worsen the prognosis dramatically and (2) to assess the
severity of the pulmonary hypoplasia. This information
is used to make a personalized prognosis and lead multi-
disciplinary counseling. Additional evaluation frequently
reveals some elements of discordance with the initial as-
sessment at the referring site and may well result in a
changed perspective and different parental decisions
[10]. Therefore, it is considered prudent to limit prog-
nostic advice at first diagnosis.
Fig. 1 Fetal endoscopic tracheal occlusion (FETO): a schematic drawing showing access to uterus and the fetal trachea. Inserts: steps in balloon
delivery. © UZ Leuven, UZ Leuven, Belgium, drawing Myrthe Boymans
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In isolated cases, personalized prediction of outcome
is based on measurements of lung size, liver position,
and the side of the defect [11]. Although other charac-
teristics are being investigated among which stomach
position, pulmonary circulatory parameters, and cardiac
ventricular size as additional prognostic indicators, the
lung-to-head-ratio (LHR) remains the best studied
parameter for prediction. The lung contralateral to the
lesion is measured in the standard plane for a four-
chamber view of the heart, and the head circumference
is measured in a standard biparietal view (Fig. 2a, b)
[12]. The most accurate way of measuring the lung is by
tracing its outline [13]. The LHR measured in the index
case (observed) is expressed as a percentage (o/e LHR;
%) of what one would expect in a normal fetus at a
similar gestational age (expected). MRI is now almost
ubiquitously used in tertiary centers for evaluation of
congenital anomalies. In CDH cases, MRI allows for
volumetric measurement of both lungs, the ability to
quantitate the degree of liver herniation, and a detailed
assessment of stomach position. So far, fetal MRI lung
volumetry in CDH does not provide improved outcome
prediction over ultrasound; hence, we do not use it for
decisions regarding FETO. The predictive value of im-
aging methods in terms of pulmonary hypertension or
extra-corporeal membrane oxygenation needs is cur-
rently under review [14].
Fetuses from singleton pregnancies with a predicted
poor postnatal outcome are the target group for fetal
intervention. The o/e LHR, presence of the liver in the
thorax, and the side of the defect are used so stratify
these fetuses [15] (Fig. 2c, d). Babies born beyond
30 weeks with a left-sided CDH, a herniated liver, and
an o/e LHR < 25% who are managed with standard post-
natal therapy have a survival rate that is < 20% [11].
These parameters were therefore used to define that
group of fetuses with severe pulmonary hypoplasia, and
they formed the initial study population for prenatal
therapy. Despite encouraging early experience with
FETO [16], fetal surgery for isolated CDH is still consid-
ered experimental. Patients with a fetus who has an iso-
lated LCDH and severe lung hypoplasia are currently
being offered participation in a global randomized clin-
ical trial (https://www.totaltrial.eu/) comparing out-
comes of FETO to expectant management during
pregnancy, followed by standardized postnatal therapy
Fig. 2 The o/e LHR is calculated by taking the ratio of the lung area divided by the head circumference, compared to a reference value for that
gestational age. a Head circumference. b Lung area and diameter measured in the plane of the four-chamber view, the lung is posterior to the
heart. c Survival rates of fetuses with left-sided CDH expectantly managed during pregnancy, as a function of different o/e LHR and liver position.
d Same, for fetuses with right-sided CDH. Yellow arrows indicate improved survival after FETO as reported by Jani et al. 2006 (left CDH) and
DeKoninck et al. 2014 (right CDH) [11, 26]. Adapted, with permission, from Russo et al. 2017 [27]
Van der Veeken et al. Gynecological Surgery  (2018) 15:9 Page 3 of 9
[17]. In a second experimental arm to this trial, patients
with a CDH fetus with moderate pulmonary hypoplasia
(which has a 50% or greater survival rate) are random-
ized to FETO or expectant management, in an effort to
reduce oxygen dependency at 6 months of age. For
RCDH, fetal therapy is offered in case of severe hypopla-
sia (o/e LHR < 45%) because they have a predicted sur-
vival rate of 17%. For patients who have a more complex
presentation with additional findings, a more individual-
ized approach can be taken, yet in the absence of proof
of benefit, this is debatable[18, 19].
FETO or PLUG procedure
FETO was initially performed at 24–28 weeks only in cases
of severe CDH and under epidural anesthesia. Today, the
procedure is typically performed under local anesthesia at
27–29 weeks with conscious sedation optional, yet loco-
regional can be done when clinically required. In moderate
cases, FETO is done at 30–32 weeks. We use prophylactic
tocolysis (atosiban or alternatively indomethacin or nifedi-
pine) and antibiotics (cefazolin 2 g i.v. 8 hourly) until 24 h
after the procedure. The patient is positioned in a dorsal su-
pine position (with lateral tilt to prevent caval compression)
such that there is direct access to the fetal mouth. External
fetal manipulation may be required. Once in the appropriate
position, we administer pancuronium (0.2 mg/kg) or
equivalent, atropine (20 μg/kg), and fentanyl (15 μg/kg)
intra-muscularly through a 22 G needle to the fetus to pro-
vide analgesia, immobilization, and prophylaxis against
bradycardia. After sterile draping, the insertion trajectory is
infiltrated with local anesthesia (lidocaine 1% 10–20 mL). A
skin-incision is made and a disposable flexible 10 Fr cannula
(3.3 mm; RCF 10.0 Check-Flo Performer, Cook, Blooming-
ton, IN) loaded with a pyramidal trocar (11650TG, Karl
Storz, Tutlingen, Germany) is inserted into the amniotic
cavity under ultrasound guidance, in an area devoid of
placenta and as perpendicular as possible to the nose tip
(Additional file 1: Video S1; Fig. 3). Some introduce the can-
nula using the Seldinger technique [20].
The fetoscope is a 1.3-mm fiber optic endoscope
(11540AA, Karl Storz) housed within a curved 3.3-mm
sheath (11540KE; Karl Storz) with a delivery catheter (Bal-
tacci-BDPE-100 0.9 mm; Balt, Montmorency, France) that
is loaded with a detachable inflatable latex balloon with
integrated one-way valve (Goldbal2). These are used “off-
label” as they were originally designed for endovascular
occlusion. The inflated balloon accommodates for an
increasing tracheal diameter during pregnancy. A stylet
(11506P; Karl Storz) and grasping forceps (11510C, Karl
Storz) are available to puncture and remove the balloon
should it be incorrectly positioned (Fig. 4). We flush
warmed crystalloid (Hartmann’s solution or Ringer’s
Lactate) through the fetoscope sheath in order to distend
the larynx, clear the debris, and improve vision.
Landmarks for balloon insertion are progressively the
tip of the nose, philtrum, tongue, the raphe of the pal-
ate, uvula, epiglottis, and ultimately the vocal cords
(Additional file 2: Video S2; Fig. 5). The fetoscope is ad-
vanced into the trachea until the carina is visualized, or
if that is not possible, at least to a point where the tra-
cheal rings and pars membranacea can be positively
identified. The balloon is then advanced out of the feto-
scope, positioned between the cords and the carina,
and inflated with 0.6 mL of isotonic saline. Once in-
flated, the balloon is detached (Additional file 3: Video
S3; Fig. 6a). Finally, excessive amniotic or irrigation
fluid is drained until a normal volume is achieved. In
our initial experience, the median duration of FETO
Fig. 3 Transabdominal trocar entry in the direction of the tip of the nose. © UZ Leuven, UZ Leuven, Belgium
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was 10 min (range 3–93 min). Operating time depends
mainly on operator experience and on the position of
the fetus and is directly related to the risk of chorionic
membrane separation and amniorrhexis.
Follow-up
Patients are followed with ultrasound every 1 to 2 weeks
until the preset time for reversal of the occlusion. The fetus
is evaluated for growth, movement, general wellbeing and
routine antenatal care, and the cervical length is measured
to estimate the risk for preterm birth. Amniotic fluid vol-
ume is measured to exclude polyhydramnios as this is
common in CDH and can increase the risk of amniorrhexis
and/or preterm labor. Amniodrainage is performed when
the deepest vertical pool exceeds 12 cm. The membranes
are inspected for amnion-chorion membrane separation.
At each visit, the balloon is visualized since spontaneous
deflation has been described [21]. The tracheal balloon
appears on ultrasound as a hypoechoic fluid-filled structure
without color Doppler flow and positioned just beneath
the vocal cords between the common carotid arteries (Fig.
6b). Within a week following FETO, the fetal lung in re-
sponders becomes hyperechogenic. The parenchymal di-
mensional changes are quantified via the o/e LHR or MRI.
Volume changes precede the vascular response. In case of
amniorrhexis or preterm labor, the patients are admitted
and management is individually planned for timely and
safe balloon removal. Chorioamnionitis is the most com-
mon complication of membrane rupture and may mandate
balloon removal and delivery. Antepartum hemorrhage has
been described yet is in our experience uncommon [21].
UNPLUG or balloon removal
Our policy is to remove the balloon in utero even if deliv-
ery is imminent. It triggers lung maturation, increases sur-
vival chances, reduces morbidity [22, 23], and permits
Fig. 4 Fetoscope, fetoscopic forceps, and stylet, courtesy of KARL STORZ Endoskope, Tuttlingen, Germany
Fig. 5 Landmarks used for guidance from the tip of the nose to trachea. Up from left to right: tip of nose, upper lip, tongue, raphe palate, and
uvula. Down from left to right: epiglottis, vocal cords, trachea with inwards bulging pars membranacea, trachea more expanded and also better
visualization of the tracheal rings, and carina. © UZ Leuven, UZ Leuven, Belgium
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vaginal delivery. Removal of the balloon is scheduled at
34 weeks gestational age based on observations in sheep.
In 28% of cases, balloon removal will be indicated earlier
because of impending delivery [23]. Steroids are given to
enhance lung maturation. The removal takes place in
essentially the same preparation as described above for
balloon placement, with the same fetal and maternal med-
ications. The balloon can be punctured directly using a
20-22G needle under ultrasound guidance and in our ex-
perience is expulsed spontaneously. (Additional file 4:
Video S4). In such cases, tracheal patency can be con-
firmed by demonstration of tracheal fluid movement with
Doppler (Additional file 5: Video S5), change in tracheal
diameter, or by MRI. The balloon can also be
fetoscopically removed, which provides direct visualization
of unobstructed airways (Additional file 6: Video S6). In
the event that fetoscopic in utero removal is not possible,
we resort to tracheoscopic removal (Table 1 for instru-
ments) with the baby on placental circulation under loco-
regional anesthesia (Fig. 7 and Additional file 7: Video S7).
The fetal head and shoulders are delivered and direct
laryngo-tracheoscopy is performed. In the worst (and not
desirable) scenario, postnatal puncture from above the
manubrium sterni is used, with or without ultrasound
guidance, or by tracheoscopy. In a report on 302 cases,
67% of balloon removals were by fetoscopy, 21% by punc-
ture, and 10% by tracheoscopy on placental circulation,
and 1% ex utero [23]. In that study, the technique used
Fig. 6 a After detachment the balloon can be seen through the vocal cords which are in this case just above it. b On ultrasound the balloon is visible
as a hypoechogenic area. Power Doppler can help to distinguish the balloon from the adjacent blood vessels. © UZ Leuven, UZ Leuven, Belgium
Table 1 Overview of the fetoscopic instruments used for FETO and UNPLUG
Fetal tracheoscopy Description ID
1.3 mm endoscope Miniature telescope, with remote eyepiece 0° straight forward, 30.6 cm working length 11540AA
3.3 mm sheath Blunt curved sheath, with sand-blasted echogenic tip with stop cock for irrigation and two side
openings
11540KE
1.0 mm forceps Retrieval forceps, double action jaws, 35 cm long 11510C
0.4 mm stylet Single use puncture stylet with adjustable torque, 50 cm long 11506P
0.9 mm needle Puncture needle to protect the catheter or for aspiration, length 35 cm, can house the stylet 11540KD
3.3 mm trocar 10 Fr pyramidal tipped trocar for use with flexible cannula RCF-10.0 (Cook, Check Flo Performer) 11650TG
0.6 mL balloon Goldbal 2 detachable latex balloon with radio-opaque inclusion, outer diameter 1.5 mm (inflated:
7.0 mm); length 5.0 mm (inflated 20.0 mm)
Goldbal 2 (Balt)
0.9 mm microcatheter catheter loaded with mandrel, and Touhy Boost Y-connection, max outer diameter 0.9 mm, tapered
to 0.4 mm, 100 cm in length
“Baltacci” e BDPE
100 (Balt)
Direct bronchoscopy
1.3 mm endoscope
Miniature telescope, with remote eyepiece 0° straight forward, 18.8 cm working length 10040AA
Straight bronchoscopic
sheath
4.2 mm outer, 3.5 mm inner diameter 18.5 cm length (size 2.5), is conventional neonatal “Doesel-
Huzly” bronchoscope, with blanking and suction plug
10339F
10924SP
10315RV
Telescope bridge Houses telescope and has side opening for irrigation 1.5 mm outer diameter 10338LCI
1.0 mm forceps 19 cm semi-flexible forceps for balloon retrieval 10338H
0.4 mm stylet Single use puncture stylet with adjustable torque, 50 cm long 11506P
Endoscopic instruments were developed by Karl Storz Endoskope, supported by the European Commission in the 6th framework program. The balloon system is
an adapted version of a commercially available vascular occlusion device. Most instruments and devices are used off label
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appeared to be dictated mainly by operator preference.
There was no difference in gestational age at delivery
whether the balloon was punctured or removed by fetos-
copy. The importance of immediate availability of trained
and experienced operators who can remove a FETO
balloon rapidly and safely cannot, and must not, be under-
estimated. To our knowledge, the only neonatal deaths
directly due to balloon removal difficulties that have
occurred happened when delivery took place in an unpre-
pared and/or inexperienced environment [23].
Reported adverse events and side effects with FETO are
rare. Fetal tracheomegaly is a recognized entity that usu-
ally presents as a barking cough on effort and then re-
solves over time with minimal long-term implications.
There are a few neonates who have had significant long-
term tracheal issues, and these appear to have been related
to traumatic balloon removal or early insertion < 26 weeks
[24]. This is however an aspect that requires more detailed
and long-term follow-up. The main maternal-fetal compli-
cation is that of chorionic membrane separation and
PPROM with resultant preterm birth. Although the me-
dian gestational age at birth is 35 weeks, up to one in three
patients deliver prior to 34 weeks, potentially offsetting
the effect of the fetal intervention.
Results
To date, the published data are predominantly based on
observational trials and small case series [8]. There is one
randomized controlled trial [25, 26] that showed benefit of
FETO; however, in that study all deliveries were by EXIT
procedure, there was a case mix of right and left CDH, and
the methodology was substantially different to what is cur-
rently being practiced in Europe and the USA.
Compared to historical controls of similar severity,
FETO increases survival rate from 24 to 49% in LCDH
with o/eLHR < 25% and from 17 to 42% in RCDH with o/
eLHR < 45% [21, 26] (Fig. 2c, d). FETO also seems to re-
duce early neonatal respiratory morbidity.
Discussion
This potential benefit is now being investigated in two
parallel randomized clinical trials (RCT) “Tracheal Occlu-
sion To Accelerate Lung growth” (https://www.totaltrial.
eu/), in fetuses with LCDH and either severe or moderate
lung hypoplasia (NCT01240057 and NCT00763737).
Current fetal treatment centers are in Leuven, Belgium;
Paris, France; London, UK; Barcelona, Spain; Milan and
Rome, Italy; Bonn, Germany; Toronto, Canada; Brisbane,
Australia; and Houston, Texas, USA. These centers have a
high volume fetoscopy program, completed a minimum
learning curve of 15 FETO procedures, and committed to
strict adherence to a prenatal and postnatal management
protocol. The trial has recruited at the time of writing over
165 (moderate) and over 50 (severe) patients. Results are
expected within the next 2 years at the current recruit-
ment rate (moderate). We anticipate that more centers in
the USA and in Japan will be joining the task force which
may accelerate recruitment.
Conclusions
FETO may alter the natural history of congenital diaphrag-
matic hernia, and early clinical results look promising. It is
Fig. 7 Schematic drawing of tracheoscopic removal on placental circulation under loco-regional anesthesia. © UZ Leuven, UZ Leuven, Belgium,
drawing Myrthe Boymans
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hoped that the ongoing TOTAL trial will result in proof of
benefit. FETO is an invasive technique associated with a
significantly increased risk for preterm birth which poten-
tially tempers its benefits. The procedure requires specific
skills and instrumentation and permanent services and is at
present limited to a select group of centers. If proven effect-
ive, this procedure is likely to be implemented more widely
and appropriate dissemination will require an extensive
training program and careful oversight in order to ensure
safe implementation.
Additional files
Additional file 1: Video S1. The trocar is inserted into the amniotic
cavity under ultrasound guidance, in an area devoid of placenta and as
perpendicular as possible to the nose tip. Copyright: UZ Leuven, Leuven,
Belgium. (MP4 4355 kb)
Additional file 2: Video S2. The subsequent landmarks are seen as the
fetoscope is advanced to the fetal trachea. Chronologically: lower lip,
tongue, uvula, soft palate, epiglottis, vocal cords, and tracheal pars
membranacea. Copyright: UZ Leuven, Leuven, Belgium. (AVI 4860 kb)
Additional file 3: Video S3. The balloon is inflated with 0.6 mL of
isotonic saline solution and fills the trachea just distal to the cords,
following which it is detached. Copyright: UZ Leuven, Leuven,
Belgium. (AVI 6806 kb)
Additional file 4: Video S4. The balloon is punctured under ultrasound
guidance using a 20–22 G needle. The needle is inserted as close as
possible to the anterior shoulder, which enables to pass the umbilical
cord which is lying on the neck. As the balloon is punctured, the trachea
can be seen collapsing. Copyright: UZ Leuven, Leuven, Belgium. (MP4
5472 kb)
Additional file 5: Video S5. After puncturing, the balloon tracheal
patency can be confirmed by demonstration free tracheal fluid
movement with Doppler. Copyright: UZ Leuven, Leuven, Belgium. (MP4
3849 kb)
Additional file 6: Video S6. Fetoscopic unplugging provides direct
documentation of free airways. As the lung fluid egresses, the pressure
drops and the trachea will slightly collapse. Copyright: UZ Leuven,
Leuven, Belgium. (AVI 2303 kb)
Additional file 7: Video S7. If not possible to puncture the balloon
ultrasound guided or fetoscopic guided, we can resort to tracheoscopic
removal on placental circulation under loco-regional anesthesia. Copyright: UZ
Leuven, Leuven, Belgium. (MP4 6707 kb)
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